Mentari Therapeutics Balance Sheet Analysis
Values in millions USD
| Breakdown | FY 2025 |
|---|---|
| Period ending | Dec 2025 |
| Current Assets | |
| Cash and Cash Equivalents | 46.26 |
| Cash & Short-Term Investments | 46.26 |
| Accounts Receivable | - |
| Inventory | - |
| Other Current Assets | 0.04 |
| Total Current Assets | 46.30 |
| Non-Current Assets | |
| Property, Plant & Equipment (Net) | - |
| Other Non-Current Assets | - |
| Total Non-Current Assets | - |
| Total Assets | 46.30 |
| Current Liabilities | |
| Accounts Payable | 9.39 |
| Accrued Liabilities | 0.88 |
| Other Current Liabilities | - |
| Total Current Liabilities | 10.26 |
| Non-Current Liabilities | |
| Long-Term Debt | - |
| Other Non-Current Liabilities | - |
| Total Non-Current Liabilities | 55.08 |
| Total Liabilities | 65.34 |
| Stockholders' Equity | |
| Common Stock | 0.00 |
| Retained Earnings | -19.43 |
| Additional Paid-in Capital | 0.39 |
| Shares Outstanding | 58.30 |
| Total Stockholders' Equity | -19.04 |
| Total Liabilities & Equity | 46.30 |
Source: Company financial statements from annual and quarterly filings. Data as of Mar 31, 2026. Data sources and methodology
